Mage Biologics aims to progress a novel, orally administered monoclonal antibody
News
Abionyx manufactures a new batch of ApoA-I CER-001
The vital second batch represents a critical step on the candidate’s pathway to regulatory approval
First dose completed in phase 1 cannabinoid study
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile
ABPI reacts to new vital vaccination report
New HSCC document deems the UK’s vaccination position to be at risk
Vantage Biosciences launched to take on diabetic eye disease
The new company’s core mission is to boost patient access to disease-modifying treatments
MSD’s HCV report calls for key elimination boosts
The advice includes a national rollout of the HCV GP champion programme and further testing
AstraZeneca links up with Qureight on lung disease research
The company will utilise Qureight’s AI technology to undergo studies across a variety of complex lung diseases
Crescendo widens pivotal solid tumour therapy trial
The CB307 study expansion involves the addition of a new pembrolizumab combination cohort
EMA positive opinion for ViiV’s cabotegravir
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals
Janssen’s Talvey receives positive CHMP opinion
The treatment is a monotherapy for treating adult patients with refractory or relapsed multiple myeloma
Teva UK launches GoResp Digihaler
The inhaler supports appropriate individuals presenting with asthma and chronic obstructive pulmonary disease
CatalYm highlights GDF-15 as main anti-PD-1 resistance factor
Data underlines the significance of the company’s anti-GDF-15 antibody candidate, visugromab
UCB announces EMA bimekizumab verdict
In two studies the therapy demonstrated improvements when compared with the placebo
Grifols announces phase 3 progress for Albutein
Therapy has the potential to decrease mortality rates in patients with decompensated cirrhosis
Members of the Alliance for Genomic Discovery revealed
Illumina and Nashville Biosciences’ have announced AbbVie, Amgen, AstraZeneca, Bayer and Merck as founding members
